Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
HLX22 Phase I in Advanced HER2+ Solid Tumors
NCT03916094Phase 1Completed
- Sponsor
- Henlius
- Start
- Jul 2019
- Primary completion
- Jan 2021
- Modality
- Prophylactic Vaccines, Therapeutic Vaccines, Monoclonal Antibodies
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of hlx22 in solid tumor, sponsored by Henlius. Primary endpoint: Maximum Tolerated Dose. Started Jul 2019; status: completed.
02
Drugs
hlx22
03
Conditions
solid tumor
Beyond the preview
Go deeper on NCT03916094.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03916094.